Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis

ConclusionThe overall incidence of lapatinib-induced cardiac toxicity was relatively low based on an indirect comparison with trastuzumab. However, careful monitoring of cardiac toxicity is still needed when patients are treated with lapatinib because the related risk factors have not been clearly identified.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research